THIS IS NOT A DAY TRADE STOCK
THIS STOCK HAS AVERAGED 28% PER YEAR FOR 10 YEARS STRAIGHT
2013 2 for 1 stock split
2004 2 for 1 stock split
West Pharmaceutical Services, Inc. manufactures components and systems for injectable drug delivery and plastic packaging, and delivery system components for the healthcare, personal care, and consumer products markets. The company operates in two segments, Pharmaceutical Systems and Tech Group. The Pharmaceutical Systems segment engages in the design, manufacture, and sale of various elastomer, metal, and plastic components used in parenteral drug delivery for the pharmaceutical, generic, and biopharmaceutical industries. It offers various pharmaceutical packaging components, such as stoppers and discs, plungers, seals, dropper bulbs, needle shields and tip caps, and sterile devices. This segment also provides contract analytical laboratory services for testing and evaluating primary drug packaging components. The Tech Group segment produces injection molded components and devices, such as contact lens storage kits, pill dispensers, and disposable blood collection systems for surgical, ophthalmic, diagnostic, and drug delivery systems. This segment also involves in the manufacture and assembly of systems and devices used for nasal, oral, pulmonary, and injectable delivery of drugs used to treat diseases. The company's customers include pharmaceutical, biotechnology, generic drug, and medical-device producers. West Pharmaceutical sells its products primarily in the United States,Asia,Germany,France,and other European countries. It markets its products and services principally through its own sales force and distribution network, as well as through sales agents and distributors. The company was founded in 1923 and is headquartered in Lionville, Pennsylvania.
West Pharmaceutical Services Inc.'s Corporate Governance Quotient (CGQ®) as of 1-Apr-08 is better than 97.2% of S&P 600 companies and 97.9% of Health Care Equipment & Services companies.
Improving Global Healthcare
West helps improve the safe delivery of pharmaceutical, health care and personal care products. Media Relations Contact for North and South America
Second Quarter 2016 Highlights
- Reported net sales of $388.0 million grew 7.9% over the prior-year quarter. Net sales at constant currency grew by 8.2%.
Second quarter 2016 reported diluted EPS was $0.60 as compared to $0.38 in the prior-year quarter. Excluding restructuring and retirement charges from both periods, adjusted diluted EPS was $0.59, a growth of 26% over the prior-year quarter.
Raising full-year 2016 net sales and the lower-end of adjusted diluted EPS guidance range.
- Full-year net sales are now expected to be between $1.505 billion and $1.520 billion compared to prior range of $1.49 billion to $1.51 billion.
Full-year 2016 adjusted diluted EPS is now expected to be between $2.15 and $2.25 compared to a prior range of $2.12 to $2.25.
"Adjusted diluted EPS" and "net sales at constant currency" are Non-GAAP measurements. See discussion under the heading "Non-GAAP Financial Measures" in this release.
"We had a successful quarter with solid organic sales growth, increased gross and operating profit margins and new product launches and approvals," said Eric M. Green, President and Chief Executive Officer. "Led by our Commercial group, both the Proprietary Products and Contact-Manufactured Products segments contributed to overall organic sales growth, with broad-based growth in all three market units of Biologics, Generics and Pharma. We continue to see double-digit sales growth in our high-value product offerings including Westar RS® and Westar RU®, Daikyo®, FluroTec® and NovaPure® components."
"We had another strong quarter of gross margin expansion fueled by high-single digit organic sales growth, favorable product mix and operational efficiencies. I am pleased that our Global Operations initiatives are successfully increasing throughput and reducing lead times. As a result, we saw a sequential quarterly reduction in backlog levels and remain on track with our target of achieving faster lead times in the second half of the year and reducing backlog levels that better match underlying demand."
"Earlier this month, the U.S. Food and Drug Administration (FDA) approved the first combination product that incorporates an injectable drug with West's SmartDose® technology for use in the United States. This milestone exemplifies West's strategy of providing the highest quality components and systems to meet our customers' needs for injectable drug delivery solutions; in this case, an integrated containment system that combines the novel SmartDose device with a Daikyo Crystal Zenith® container and a Flurotec® piston. I am proud of the work of our Innovation and Technology team and partners to achieve this milestone. The many years of work and dedication to this project have paved the way for new opportunities for the on-body delivery of injectable drugs."
Mr. Green concluded, "Since the launch of our market-led strategy and business realignment at the start of the year, our teams have performed well, and the company is well positioned for future success. We continue to see solid end-market demand in our Proprietary Products segment and expect to see higher organic sales growth in our Contract-Manufactured Products segment in the second half of the year. With these trends, we are raising our full-year 2016 organic sales growth guidance to a new range of between 7% and 9% and are raising the lower-end of our adjusted diluted EPS guidance